RallyBio Partners With JJ Gets 6.6M Funding, Stock Up
FGEN Stock | USD 1.14 0.01 0.88% |
About 55% of FibroGen's investor base is interested to short. The analysis of the overall investor sentiment regarding FibroGen suggests that many traders are impartial. FibroGen's investor sentiment overview provides quick insight into current market opportunities from investing in FibroGen. The current market sentiment, together with FibroGen's historical and current headlines, can help investors time the market. In addition, many technical investors use FibroGen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
FibroGen stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of FibroGen daily returns and investor perception about the current price of FibroGen as well as its diversification or hedging effects on your existing portfolios.
FibroGen |
RallyBio gains 83 percent after announcing a collaboration deal with JJ to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of 6.6 million from the latter.
Read at finance.yahoo.com
FibroGen Fundamental Analysis
We analyze FibroGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FibroGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FibroGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
FibroGen is currently under evaluation in cash per share category among related companies. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
FibroGen Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with FibroGen stock to make a market-neutral strategy. Peer analysis of FibroGen could also be used in its relative valuation, which is a method of valuing FibroGen by comparing valuation metrics with similar companies.
Peers
FibroGen Related Equities
AKRO | Akero Therapeutics | 12.46 | ||||
LRMR | Larimar Therapeutics | 6.05 | ||||
ZURA | Zura Bio | 5.96 | ||||
HEPA | Hepion Pharmaceuticals | 5.80 | ||||
VSTM | Verastem | 5.21 | ||||
MREO | Mereo BioPharma | 5.16 | ||||
ARDX | Ardelyx | 4.93 | ||||
BMEA | Biomea Fusion | 3.52 | ||||
DAWN | Day One | 3.43 | ||||
STOK | Stoke Therapeutics | 2.82 | ||||
RVMD | Revolution Medicines | 2.58 | ||||
PCVX | VaxcyteInc | 2.18 | ||||
GLUE | Monte Rosa | 1.95 | ||||
MRUS | Merus BV | 1.81 | ||||
SNDX | Syndax Pharmaceuticals | 0.87 | ||||
BPMC | Blueprint Medicines | 0.18 | ||||
AGIO | Agios Pharm | 0.12 | ||||
CGEM | Cullinan Oncology | 0.18 | ||||
AVRO | AVROBIO | 0.81 | ||||
BMRN | Biomarin Pharmaceutical | 1.62 | ||||
STRO | Sutro Biopharma | 2.79 | ||||
GOSS | Gossamer Bio | 3.90 | ||||
LYEL | Lyell Immunopharma | 7.09 |
Check out FibroGen Hype Analysis, FibroGen Correlation and FibroGen Performance. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for FibroGen Stock analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.